linjc16/ctgov huggingface dataset:
Assessment of the Prevalence of Lysosomal Acid Lipase Deficiency in Patients Waiting for a Liver Transplant.

Study Overview
=================
Brief Summary
-----------------
Lysosomal Acid Lipase (LAL) deficiency is a rare, autosomal recessive storage disease linked to decrease enzymatic activity of LAL, responsible for intracellular accumulation of cholesterol esters and triglycerides. The accumulation of lipid is in hepatocytes, Kupffer cells and macrophages leading to a fatty liver, hepatic fibrosis that can evolve up to cirrhosis. LAL deficiency is responsible for significant morbidity and early mortality in children, adolescents and adults in connection with a multi visceral disease reaching the liver, gastrointestinal tract and the vascular endothelium. The disease is caused by homozygous or heterozygous mutations in the gene (LIPA chromosome 10q23.2-23.3) which is responsible for the synthesis of the LAL. The disease can be diagnosed by enzymatic analysis using few drops of blood absorbed onto blotting paper . Patients with this deficiency LAL, have no or reduced activity of this enzyme. Because of its rarity, the deficit in LAL is under diagnosed or is diagnosed in patients with liver biological disturbances and / or lipid profile disturbances, steatohepatitis-hepatitis (NASH), the steatosis (NAFLD), the cryptogenic cirrhosis or Wilson disease. Inclusion period of 12 to 18 months (100 patients).

Official Title
-----------------
Assessment of the Prevalence of Lysosomal Acid Lipase Deficiency in Patients Waiting for a Liver Transplant.

Conditions
-----------------
Patients Waiting for a Liver Transplant.

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients registered on the liver transplant waiting list. patients with cryptogenic cirrhosis, NASH Exclusion Criteria: Patients without metabolic syndrome clinical, biological or radiological.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Deficiency Lysosomal Acid Lipase prevalence in patients waiting for a liver transplant | Assessment of deficiency Lysosomal Acid Lipase prevalence in patients waiting for a liver transplant | During the routine visit (Day 1) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
liver, transplant, Lysosomal Acid Lipase
Effect of a Tracking Program on Colon Adenoma Surveillance and Adherence to Guideline Recommendations

Study Overview
=================
Brief Summary
-----------------
This will be a retrospective chart review of 880-1000 patients who had a colonoscopy and were found to have a tubular adenoma between the years of 2004-2008. We will compare the rate and timing of completion of repeat colonoscopies pre and post establishment of a polyp registry (tracking system) in 2006. Each group will be composed of up to 500 subjects consecutively identified from all the patients who underwent colonoscopy and were found to have a tubular adenoma (Group 1-2004 to 2006, Group 2 2007-2008).

Detailed Description
-----------------
This will be a retrospective chart review of 880-1000 patients who had a colonoscopy and were found to have a tubular adenoma between the years of 2004-2008. We will compare the rate and timing of completion of repeat colonoscopies pre and post establishment of a polyp registry (tracking system) in 2006. Each group will be composed of 380-500 subjects consecutively identified from all the patients who underwent colonoscopy and were found to have a tubular adenoma (Group 1-2004 to 2006, Group 2 2007-2008).

Official Title
-----------------
Effect of a Tracking Program on Colon Adenoma Surveillance and Adherence to Guideline Recommendations

Conditions
-----------------
Colon Polyp Surveillance

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any adenoma found on screening/surveillance colonoscopy (ICD9-211.3, Procedure code 45385 or 45380) Greater than 18 years old Exclusion Criteria: Less than 18 years old Diagnosis of IBD

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| post-registry<br>Registry Group: Select 500 consecutive patients from the polyp registry who were found to have a tubular adenoma on a colonoscopy done between 2007-2008 from the polyp registry. Quantify the completion rate and time between index and surveillance colonoscopy after the establishment of the polyp surveillance program (2006-2013). | |
| pre-registry<br>Pre-registry Group: Select 380 consecutive patients who were found to have a tubular adenoma on a colonoscopy done between April 2004-Nov 2006. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage completing follow up colonoscopy | A polyp tracking program (registry) decreases the amount of patients lost to follow up. | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Polyp, colonoscopy, surveillance
Gut Microbiome Dysbiosis in Sepsis-induced Coagulopathy

Study Overview
=================
Brief Summary
-----------------
In the diagnosis and treatment of patients with sepsis, through routine stool testing and dynamic testing of coagulation function, we found that patients often have stools that are not formed, the proportion of main fecal bacteria is imbalanced, the level of blood bacterial toxins rises, and the abnormal coagulation status indicate the gut microbiome dysbiosis may play an important regulatory role in abnormal blood coagulation in patients with sepsis. Therefore, we propose that the gut microbiome dysbiosis is involved in sepsis-induced coagulopathy. This project intends to prospectively observe the changes in gut microbiome dysbiosis and blood coagulation function in patients with sepsis before and after treatment, and explore whether the changes in gut microbiome dysbiosis promote the development of sepsis through coagulation disorders, provide new research perspectives for diagnosis and treatment for sepsis.

Official Title
-----------------
Gut Microbiome Dysbiosis in Sepsis-induced Coagulopathy

Conditions
-----------------
Sepsis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 years and ≤85 years Sign the informed consent form Expected ICU hospital stay> 24 hours △SOFA score ≥2 and confirmed or suspected infection Exclusion Criteria: Pregnant or breastfeeding women Estimated survival time <24 hours Diagnosis of sepsis time> 24 hours The length of ICU stay before diagnosis of sepsis> 7 days Sepsis from which the source of infection cannot be determined Congenital coagulopathy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gut Microbiome alterations | Taxonomic alterations,bacterial alpha diversity alterations,beta-diversity alterations of gut microbiome by performing metagenomic sequencing analysis of fecal samples | Day 1- Day 14 | 
| coagulation disorder tests | Laboratory tests of coagulation disorder,such as PT,APTT,INR,TEG,fibrin degradation products , D-dimers. | Day 1- Day 14 |
Glaucoma Treatment by Cyclo-coagulation Using High Intensity Focused Ultrasound (HIFU)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effectiveness and the safety of the cyclocoagulation using High Intensity Focused Ulatrsound with the EYEOP1 device in glaucoma patients

Official Title
-----------------
Glaucoma Treatment by Cyclo-coagulation Using High Intensity Focused Ultrasound With the EyeOP1 Medical Device.

Conditions
-----------------
Glaucoma

Intervention / Treatment
-----------------
* Device: EYEOP1


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Refractory Glaucoma IOP > 21 mm Hg No previous intraocular surgery or laser treatment during the 90 days before HIFU day Age > 18 years Informed consent sgned by the subject Exclusion Criteria: Normal Tension Glaucoma Glaucoma drainage device implanted and still present in the eye to be treated History of ocular or retrobulbar tumor Ocular infection within 14 days prior to the HIFU procedure Aphakic patient Ocular disease other than glaucoma that may affect assessment of visual and/or IOP (choroidal hemorrhage or detachment, lens subluxation, thyroid ophthalmopathy, proliferative diabetic retinopathy, clinical significant macular edema) Pregnant or breast-feeding women, or lack of contraception use among women likely to have a child

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: EYEOP1 device<br>cyclocoagulation HIFU | Device: EYEOP1<br>* Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP1 device<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy endpoint : Success / failure rate at 1 year | IOP change (mm Hg and percent) from baseline to 12 months post-HIFU treatment. (Success defined by IOP reduction > 20% compared to the baseline IOP or IOP < 21 mmHg) | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety measures | Number of device and procedure-related and others complications during follow-up | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glaucoma, Cyclocoagulation, HIFU High Intensity Focused Ultrasound
Energy Expenditure and Gastric Bypass Surgery

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to assess whether activity thermogenesis increases in patients undergoing bariatric surgery post-operatively compared to pre-operatively. The investigators will assess non-exercise activity thermogenesis using a validated Physical Activity Monitoring System and doubly labeled water, immediately pre-operatively and again at 6 and 18 months post-operatively. PAMS has been validated in lean and obese individuals. This is to assess energy expenditure, activity thermogenesis and NEAT during the phase of greatest weight loss and once weight loss has plateaued. This will permit us to address our primary hypothesis that activity thermogenesis as a fraction of total daily energy expenditure increases in patients undergoing bariatric surgery 6 and 18 months post-operatively, compared to pre-operatively.

Official Title
-----------------
Energy Expenditure and Gastric Bypass Surgery

Conditions
-----------------
Gastric Bypass Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Undergoing gastric bypass surgery, 18-60 years Exclusion Criteria: Eligible subjects will be excluded who cannot walk at 2.4 mph for 15 minutes, or weigh greater than 227 kg at the screening visit.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TDEE (total daily energy expenditure) | Activity thermogenesis as a fraction of total daily energy expenditure increases in patients undergoing bariatric surgery 6 and 18 months post-operatively, compared to pre-operatively. | March 2009 to October 2013 |
Evaluation and Monitoring of the Protocol Post Operative Atrial Fibrillation

Study Overview
=================
Brief Summary
-----------------
Objectives The aims of this study is to evaluate the efficacy and tolerance of our post-operative AF management protocol after cardiac surgery, including beta-blockers, digoxin, amiodarone. Methods This study concerns patients From brest university Hospital who underwent cardiac surgery between November 2019 and November 2021. Patients with a previous history of atrial arrhythmias were excluded. The primary endpoint is assess effectiveness of service protocol to maintain cardiac frequency below. 110 bpm. The secondary endpoints included hemodynamic tolerance and outcomes.

Detailed Description
-----------------
Background Atrial fibrillation (AF) is the most common complication after open heart surgery. Its reported incidence is about 30%, and it is associated with a significant increase rate of thromboembolic events, respiratory failure, a longer lenght of stay in hospital and mortality. (1 ;2) Gillinov's study has shown equivalent effectiveness of a rhythm control and rate control strategy, in AF patients after cardiac surgery, with increased side effects in patients treated with rhythm control agents. (3) The introduction of beta-blockers can be poorly tolerated hemodynamically in patients hospitalized in intensive care unit, unless untroducing a cardio-selective beta-blocker.. Methods Patients who underwent a cardiac surgery from Novembre 2019 to Novembre 2021 were included. Patients with a previous history of atrial arrhythmias were excluded. The primary endpoint is assess effectiveness of service protocol to maintain cardiac frequency below. 110 bpm. The secondary endpoints included hemodynamic tolerance and outcomes.

Official Title
-----------------
Evaluation and Monitoring of the Protocol for the Management of Post Operative Atrial Fibrillation Based on Intravenous Beta-blockers in Cardiac Surgery

Conditions
-----------------
Post Operative Atrial Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: POAF after cardiac surgery non-opposition formulated Exclusion Criteria: pregnant woman opposition hemodynamic unstability with inotropic drugs or CI<2 L/min/m2

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Heart Rate | HR < 110 BPM | 72 hours (3 days) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sinusal Rythm | time to be back in sinusal rythm | 72hours ( 3 days) |
A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes

Study Overview
=================
Brief Summary
-----------------
The primary objective of the study is to determine the efficacy of thalidomide for the treatment of anemia in patients with myelodysplastic syndromes (MDS).

Conditions
-----------------
Myelodysplastic Syndromes

Intervention / Treatment
-----------------
* Drug: thalidomide


Participation Criteria
=================
Eligibility Criteria
-----------------
Eligible patients must have a diagnosis of myelodysplastic syndrome Life expectancy of at least 6 months. Patients must be able to adhere to the study visit schedule and other protocol requirements. Patients must understand and voluntarily sign an informed consent document. Women of childbearing potential (WCBP) must agree to practice abstinence or to use TWO methods of contraception beginning 4 weeks prior to the start of study medication and throughout the course of treatment. Males must use barrier contraception when engaging in reproductive sexual activity with women of childbearing potential.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: thalidomide|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
The Daily Habits Survey

Study Overview
=================
Brief Summary
-----------------
Online survey for 11-17 year olds about behavior, sleep, and food consumption patterns. This survey can be completed on any computer that has internet access.

Detailed Description
-----------------
The following opportunity is a reserach project at the American University Behavioral Pharmacology and Health Promotions Laboratory (BPHP). The study population is 11-17 year olds. The 30 minute online survey asks questions about behavior, sleep, and typical food consumption. The purpose of this survey is to better understand these habits in young people and the effects of these habits on behavior and sleep. This information will provide us with a better understanding of the daily habits in young people and guide the direction of future research projects.

Official Title
-----------------
The Daily Habits Survey

Conditions
-----------------
Food Consumption, Sleep, and Behavior

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 11-17 years old

Ages Eligible for Study
-----------------
Minimum Age: 11 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Tryptophan and Behavior Therapy for Cocaine Abuse - 1

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the efficacy of tryptophan vs. placebo, and voucher payments vs. a control condition, in the treatment of cocaine dependence.

Detailed Description
-----------------
This clinical trial uses a 2 by 2 design to compare tryptophan to placebo, and voucher incentives vs. a control condition, in the outpatient treatment of cocaine dependence- using a relapse prevention model of treatment intervention.

Official Title
-----------------
Tryptophan and Behavior Therapy for Cocaine Abuse

Conditions
-----------------
Cocaine-Related Disorders

Intervention / Treatment
-----------------
* Drug: Tryptophan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cocaine dependent Exclusion Criteria: Physically dependent on drugs of abuse other than cocaine Significant medical or psychiatric illness (besides substance abuse disorder) Pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Tryptophan|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Side effects |  |  | 
| Retention |  |  | 
| Cocaine use |  |  | 
| Cocaine craving |  |  | 
| Other drug use |  |  | 
| Psychosocial functioning |  |  |
IVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry

Study Overview
=================
Brief Summary
-----------------
This is a prospective multi-center international registry. The objective of this registry is to collect prospective data on patients undergoing catheter ablation for Ventricular Tachycardia (VT) and Premature Ventricular Contractions (PVC). The registry will be used for clinical monitoring, research, and quality improvement purposes.

Detailed Description
-----------------
Sudden cardiac death (SCD), predominantly due to ventricular tachyarrhythmias, is a leading cause of mortality in the United States and around the world. Catheter ablation of ventricular arrhythmias has proven efficacious in reducing the burden of arrhythmias and reducing implantable cardiac defibrillator (ICD) shocks. The aim of this study is to create a prospective international database registry that will allow for better assessment of the outcomes of catheter ablation of ventricular arrhythmias. The registry, with approximately 30 participating centers, will help to identify the overall success rates and associated benefits of the procedure and provide more comprehensive data on understudied populations and treatment.

Official Title
-----------------
An International VT Ablation Center Collaborative Group (IVTCC): A Multicenter Ventricular Tachycardia Catheter Ablation Registry

Conditions
-----------------
Ventricular Arrhythmia, Ventricular Tachycardia, Premature Ventricular Contraction (PVC), Cardiomyopathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - All patients undergoing catheter ablation for ventricular tachycardia (VT) or premature ventricular contractions (PVCs).
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ventricular tachycardia (VT) recurrence | Freedom from ventricular tachycardia episodes requiring ICD Intervention (shock or Anti-Tachycardia Pacing) or repeat procedure. | From date of procedure assessed by shock, Anti-Tachycardia Pacing, or repeat procedure, up to 10 years. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of complications | Cardiovascular-related and procedure-related major complications and/or adverse events. | From date of procedure assessed up to 12 months. | 
| Time to transplant or death |  | From date of procedure assessed by date of transplant and/or death, up to 10 years. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Arrhythmia, Cardiac Conduction System Disease, Sudden Cardiac Death, Implantable Cardiac Defibrillator (ICD)